Trial Information

Summary: COG ANBL0032: Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue

You are/your child is being asked to take part in this study because you have/your child has been diagnosed with high-risk neuroblastoma.  You/your child has already received and responded to chemotherapy, surgery, radiation therapy, and stem cell transplant treatment on study COG-A3973.  The purpose of this companion study is to compare  the ability of two treatment programs to improve the survival of subjects who responded to treatment on COG-A3973.  This study will also evaluate these two treatment programs in terms of side effects and the results of various laboratory tests.  Your/your child’s treatment on this study is expected to last approximately 24 to 25 weeks, depending on the treatment group to which you/your child are/is assigned.  After your/your child’s treatment is over, your/your child’s medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:57 PM